Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun;128(6):1547-1567.
doi: 10.1111/jam.14478. Epub 2019 Oct 29.

Recent updates on drug resistance in Mycobacterium tuberculosis

R Singh  1 , S P Dwivedi  2 , U S Gaharwar  3 , R Meena  3 , P Rajamani  3 , T Prasad  1
Affiliations
Review

Recent updates on drug resistance in Mycobacterium tuberculosis

R Singh et al. J Appl Microbiol. 2020 Jun.

Abstract

Tuberculosis (TB) along with acquired immune deficiency syndrome and malaria rank among the top three fatal infectious diseases which pose threat to global public health, especially in middle and low income countries. TB caused by Mycobacterium tuberculosis (Mtb) is an airborne infectious disease and one-third of the world's population gets infected with TB leading to nearly 1·6 million deaths annually. TB drugs are administered in different combinations of four first-line drugs (rifampicin, isoniazid, pyrazinamide and ethambutol) which form the core of treatment regimens in the initial treatment phase of 6-9 months. Several reasons account for the failure of TB therapy such as (i) late diagnosis, (ii) lack of timely and proper administration of effective drugs, (iii) lower availability of less toxic, inexpensive and effective drugs, (iv) long treatment duration, (v) nonadherence to drug regimen and (vi) evolution of drug-resistant TB strains. Drug-resistant TB poses a significant challenge to TB therapy and control programs. In the background of worldwide emergence of 558 000 new TB cases with resistance to rifampicin in the year 2017 and of them, 82% becoming multidrug-resistant TB (MDR-TB), it is essential to continuously update the knowledge on the mechanisms and molecular basis for evolution of Mtb drug resistance. This narrative and traditional review summarizes the progress on the anti-tubercular agents, their mode of action and drug resistance mechanisms in Mtb. The aim of this review is to provide recent updates on drug resistance mechanisms, newly developed/repurposed anti-TB agents in pipeline and international recommendations to manage MDR-TB. It is based on recent literature and WHO guidelines and aims to facilitate better understanding of drug resistance for effective TB therapy and clinical management.

Keywords: Mycobacterium tuberculosis; anti-tubercular drugs; drug resistance; multidrug drug-resistant tuberculosis; tuberculosis.

PubMed Disclaimer

References

    1. Blair, J.M., Webber, M.A., Baylay, A.J., Ogbolu, D.O. and Piddock, L.J. (2015) Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol 13, 42-51.
    1. Byrne, A.L., Marais, B.J., Mitnick, C.D., Lecca, L. and Marks, G.B. (2015) Tuberculosis and chronic respiratory disease: a systematic review. Int J Infect Dis 32, 138-146.
    1. Caws, M., Duy, P.M., Tho, D.Q., Lan, N.T.N., Hoa, D.V. and Farrar, J. (2006) Mutations prevalent among rifampin- and isoniazid-resistant Mycobacterium tuberculosis isolates from a hospital in Vietnam. J Clin Microbiol 44, 2333-2337.
    1. Chen, W., Green, K.D., Tsodikov, O.V. and Tsodikova, G.S. (2012) The aminoglycoside multi-acetylating activity of the enhanced intracellular survival (Eis) protein from Mycobacterium smegmatis and its inhibition. Biochemistry 51, 4959-4967.
    1. Conde, M.B. and Silva, J.R.L.E. (2011) New regimens for reducing the duration of the treatment of drug-susceptible pulmonary tuberculosis. Drug Dev Res 72, 501-508.

MeSH terms

Substances